ArticleOncology and therapy2025

Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States.

Bradley J Monk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.